dapagliflozin;sitagliptin
- Generic Name
- dapagliflozin;sitagliptin
A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Phase 4
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT06972732
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District, Korea, Republic of
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Phase 1
Completed
- Conditions
- Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT05266404
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath